CN1305527C - 乙型肝炎治疗疫苗及其制备方法 - Google Patents
乙型肝炎治疗疫苗及其制备方法 Download PDFInfo
- Publication number
- CN1305527C CN1305527C CNB2003101137709A CN200310113770A CN1305527C CN 1305527 C CN1305527 C CN 1305527C CN B2003101137709 A CNB2003101137709 A CN B2003101137709A CN 200310113770 A CN200310113770 A CN 200310113770A CN 1305527 C CN1305527 C CN 1305527C
- Authority
- CN
- China
- Prior art keywords
- vaccine
- hepatitis
- treating hepatitis
- preparation
- hbs antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 16
- 208000002672 hepatitis B Diseases 0.000 title abstract description 44
- 229960005486 vaccine Drugs 0.000 title abstract description 40
- 239000000427 antigen Substances 0.000 claims abstract description 80
- 102000036639 antigens Human genes 0.000 claims abstract description 80
- 108091007433 antigens Proteins 0.000 claims abstract description 80
- 238000002360 preparation method Methods 0.000 claims abstract description 57
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 239000002671 adjuvant Substances 0.000 claims abstract description 26
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 12
- 229960000814 tetanus toxoid Drugs 0.000 claims description 79
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 claims description 54
- 238000010168 coupling process Methods 0.000 claims description 48
- 229940124736 hepatitis-B vaccine Drugs 0.000 claims description 47
- 230000008878 coupling Effects 0.000 claims description 45
- 238000005859 coupling reaction Methods 0.000 claims description 45
- 238000012412 chemical coupling Methods 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 201000009906 Meningitis Diseases 0.000 claims description 6
- 229910052782 aluminium Inorganic materials 0.000 claims description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 6
- 239000004411 aluminium Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 101710116435 Outer membrane protein Proteins 0.000 claims description 5
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 5
- 241001076388 Fimbria Species 0.000 claims description 3
- 230000000680 avirulence Effects 0.000 claims description 3
- 206010013023 diphtheria Diseases 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical compound OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 claims 2
- 101000963974 Hydrophis stokesii Alpha-elapitoxin-Ast2b Proteins 0.000 claims 2
- 101000964025 Naja naja Long neurotoxin 3 Proteins 0.000 claims 2
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 abstract description 11
- 230000008105 immune reaction Effects 0.000 abstract description 4
- 229940021747 therapeutic vaccine Drugs 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 description 23
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000001900 immune effect Effects 0.000 description 13
- 238000011081 inoculation Methods 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 229920001282 polysaccharide Polymers 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 108010055044 Tetanus Toxin Proteins 0.000 description 4
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 230000002584 immunomodulator Effects 0.000 description 4
- 229960001438 immunostimulant agent Drugs 0.000 description 4
- 239000003022 immunostimulating agent Substances 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 4
- 229960001627 lamivudine Drugs 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229940118376 tetanus toxin Drugs 0.000 description 4
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229940031937 polysaccharide vaccine Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 2
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 231100000749 chronicity Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- -1 il-1 2 Chemical compound 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000009781 safety test method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
疫苗批号 | 接种前体 | 接种后7天体重 | 观察期接种反应 | 结论 |
重(克) | (克) | |||
HB200201 | 268272 | 355343 | 健存,体重增加无异常反应 | 合格 |
HB200202 | 302298 | 378369 | 健存,体重增加无异常反应 | 合格 |
HB200203 | 290285 | 360349 | 健存,体重增加无异常反应 | 合格 |
疫苗批号 | 接种前体重(克) | 接种后7天体重(克) | 观察期接种反应 | 结论 |
HB200201 | 19.518.819.319.020.5 | 24.023.823.323.724.0 | 健存体重增加无异常反应 | 合格 |
HB200202 | 18.720.320.521.019.1 | 24.525.324.625.424.7 | 健存体重增加无异常反应 | 合格 |
HB200203 | 20.919.618.619.719.9 | 25.023.924.125.124.5 | 健存体重增加无异常反应 | 合格 |
组别 | 免前阳性数 | 免后阳性数 | ||
HBsAg | 抗-HBs | HBsAg | 抗-HBs | |
乙型肝炎表面抗原偶联TT与PA混合组 | 10 | 0 | 3 | 7 |
乙型肝炎表面抗原偶联TT | 10 | 0 | 5 | 5 |
乙肝疫苗组 | 10 | 0 | 9 | 1 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101137709A CN1305527C (zh) | 2003-11-21 | 2003-11-21 | 乙型肝炎治疗疫苗及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101137709A CN1305527C (zh) | 2003-11-21 | 2003-11-21 | 乙型肝炎治疗疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1618466A CN1618466A (zh) | 2005-05-25 |
CN1305527C true CN1305527C (zh) | 2007-03-21 |
Family
ID=34760049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101137709A Expired - Lifetime CN1305527C (zh) | 2003-11-21 | 2003-11-21 | 乙型肝炎治疗疫苗及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1305527C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100388953C (zh) * | 2006-06-15 | 2008-05-21 | 南京农业大学 | 口服疫苗的复合黏膜免疫佐剂 |
WO2020099927A1 (en) * | 2018-11-13 | 2020-05-22 | Variation Biotechnologies Inc. | Immunogenic compositions for treatment of hepatitis b |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1118573A (zh) * | 1993-02-26 | 1996-03-13 | 斯克瑞普斯研究所 | 诱导细胞毒t淋巴细胞应答乙型肝炎病毒的肽类 |
CN1300222A (zh) * | 1998-02-12 | 2001-06-20 | 免疫合成物公司 | 策略性修饰的乙肝核心蛋白及其衍生物 |
CN1424110A (zh) * | 2002-12-30 | 2003-06-18 | 北京市希波医学技术开发公司 | 抗乙型肝炎病毒治疗性疫苗佐剂 |
CN1454668A (zh) * | 2002-12-30 | 2003-11-12 | 北京市希波医学技术开发公司 | 抗乙型肝炎病毒治疗性疫苗及其佐剂 |
-
2003
- 2003-11-21 CN CNB2003101137709A patent/CN1305527C/zh not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1118573A (zh) * | 1993-02-26 | 1996-03-13 | 斯克瑞普斯研究所 | 诱导细胞毒t淋巴细胞应答乙型肝炎病毒的肽类 |
CN1300222A (zh) * | 1998-02-12 | 2001-06-20 | 免疫合成物公司 | 策略性修饰的乙肝核心蛋白及其衍生物 |
CN1424110A (zh) * | 2002-12-30 | 2003-06-18 | 北京市希波医学技术开发公司 | 抗乙型肝炎病毒治疗性疫苗佐剂 |
CN1454668A (zh) * | 2002-12-30 | 2003-11-12 | 北京市希波医学技术开发公司 | 抗乙型肝炎病毒治疗性疫苗及其佐剂 |
Also Published As
Publication number | Publication date |
---|---|
CN1618466A (zh) | 2005-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1091978A (zh) | 粒细胞-巨噬细胞-集落刺激因子作为疫苗佐剂的用途 | |
CN1671412A (zh) | 免疫刺激组合物及刺激免疫反应的方法 | |
JP2004002463A (ja) | インターロイキン含有安定ワクチン組成物 | |
CN1404399A (zh) | 调节包括与粘膜体表面接触的疫苗抗原的物质的作用的新的非抗原性粘膜佐剂制剂 | |
CN102949717A (zh) | 一种含poly I:C佐剂的新型乙肝疫苗制剂 | |
CN1228086C (zh) | 联合疫苗的制备方法 | |
CN109550046B (zh) | 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法 | |
CN101559223B (zh) | 流脑白百破联合疫苗 | |
CN1305527C (zh) | 乙型肝炎治疗疫苗及其制备方法 | |
CN108567977B (zh) | 一种免疫增强剂、免疫治疗药物组合物及其制备与用途 | |
CN107693788B (zh) | 一种用于预防或治疗乙型肝炎的药物组合物及其用途 | |
CN1161154C (zh) | 用于疫苗的免疫增强制剂 | |
CN1168501C (zh) | 一种多糖-蛋白结合疫苗 | |
CN1209163C (zh) | 脑膜炎球菌疫苗及其制备方法 | |
WO2018227728A1 (zh) | 一种免疫增强剂、口蹄疫灭活疫苗及其制备方法 | |
CN1218750C (zh) | 皮内注射用重组乙型肝炎卡介苗联合疫苗及制备方法 | |
CN1517124A (zh) | 具有解热作用的中药组合物及其制备方法和质量控制方法 | |
TWI827732B (zh) | 用於治療b型肝炎的藥物製劑及其製備方法和用途 | |
CN1324661A (zh) | 一种人乙型肝炎核酸疫苗 | |
CN1382735A (zh) | 生长抑素卵黄抗体及其制备 | |
CN1314449C (zh) | 乙型脑炎病毒疫苗和脑膜炎球菌结合疫苗组成的联合疫苗 | |
CN1911444A (zh) | 伤寒、副伤寒外膜蛋白疫苗 | |
CN101422609A (zh) | 香菇多糖作为丙肝病毒核酸疫苗免疫佐剂的应用 | |
CN109876140A (zh) | 一种治疗慢性乙肝的疫苗及其制备方法和应用 | |
CN1295480A (zh) | 含有白细胞介素-12和呼吸道合胞病毒抗原的疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHENGDU ANTEJIN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: XUE PING Effective date: 20131203 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 101318 SHUNYI, BEIJING TO: 610041 CHENGDU, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131203 Address after: 610041 No. 88 Park South Road, hi tech Zone, Sichuan, Chengdu Patentee after: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. Address before: 101318 Beijing City, Shunyi District Vanke City Garden No. 902 cloud Fengge Patentee before: Xue Ping |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Vaccine for treating hepatitis B, and its prepn. method Effective date of registration: 20190110 Granted publication date: 20070321 Pledgee: Chengdu Tianfu International Biological City Investment and Development Co.,Ltd. Pledgor: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. Registration number: 2018510000127 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211116 Granted publication date: 20070321 Pledgee: Chengdu Tianfu International Biological City Investment and Development Co.,Ltd. Pledgor: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. Registration number: 2018510000127 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: No.88 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610041 Patentee after: Fosun Antekin (Chengdu) Biopharmaceutical Co.,Ltd. Address before: No.88 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610041 Patentee before: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hepatitis B therapeutic vaccine and its preparation method Effective date of registration: 20230307 Granted publication date: 20070321 Pledgee: Industrial Bank Limited by Share Ltd. Chengdu branch Pledgor: Fosun Antekin (Chengdu) Biopharmaceutical Co.,Ltd. Registration number: Y2023510000063 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070321 |